Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The rationale of this study is to assess the safety profile, efficacy and adherence to Rebif®
New Formulation in real life settings with a multinational approach, as well as the impact of
this improved formulation (with regards to adverse events [AEs]) to subjects' adherence.
Details
Lead Sponsor:
Merck KGaA Merck KGaA, Darmstadt, Germany
Collaborators:
Merck A.B., Sweden Merck A.E., Greece Merck B.V., Netherlands Merck OY, Finland Merck, S.A., Portugal